公开(公告)号：US20230112418A1

公开(公告)日：2023-04-13

申请号：US17904792

申请日：2021-03-04

Applicant: NIHON MEDI-PHYSICS CO., LTD. ,  KYOTO UNIVERSITY

Inventor： Yoshifumi MAYA ,  Masahiro ONO ,  Shimpei IIKUNI

IPC: C07D487/04 ,  C07D513/04 ,  C07F5/00 ,  A61K51/04

Abstract: In a compound of the present invention, in a macroscopic view of a chemical structure thereof, a chelating moiety is located at the center of the structure, an atomic group containing an albumin binding moiety binds to one side of the chelating moiety, and an atomic group containing a target molecule binding moiety binds to the other side of the chelating moiety. The chelating moiety is also preferably DOTA or a derivative thereof. The target molecule binding moiety preferably has a structure to bind to a target molecule expressed in a cancer tissue. The present invention also provides a radioactive labeled compound in which the compound is coordinated to a radioactive metal ion.

公开(公告)号：US20190255199A1

公开(公告)日：2019-08-22

申请号：US16308014

申请日：2017-06-09

Applicant: Nihon Medi-Physics Co., Ltd.

Inventor： Yoshifumi MAYA

IPC: A61K51/04 ,  A61K9/00

Abstract: The present invention addresses the problem of providing a technique for detecting a lesion of a heart disease in a non-invasive manner. The present invention provides a non-invasive diagnostic imaging agent for a heart disease, which contains a radioactively labeled compound capable of binding to an aldosterone synthase or a salt thereof as an active ingredient.

公开(公告)号：US20240174622A1

公开(公告)日：2024-05-30

申请号：US18548716

申请日：2022-03-02

Applicant: NIHON MEDI-PHYSICS CO., LTD. ,  KYOTO UNIVERSITY

Inventor： Yoshifumi MAYA ,  Hiroaki ICHIKAWA ,  Yusuke HIGAKI ,  Masahiro ONO ,  Shimpei IIKUNI

IPC: C07D257/02 ,  A61K31/395 ,  A61K51/04 ,  C07B59/00

CPC classification number: C07D257/02 ,  A61K31/395 ,  A61K51/0482 ,  C07B59/004 ,  C07B2200/05

Abstract: The compound of the present invention includes a structure having: a chelating part capable of coordinating with a radioactive metal ion; a first atomic group containing an albumin-binding part; and a second atomic group containing a PSMA molecule-binding part, wherein the first atomic group and the second atomic group are bonded with each other through the chelating part, or the chelating part is bonded from between the first atomic group and the second atomic group so that it makes a branch. The present invention also provides: a radiolabeled compound in which the compound is coordinated with a radioactive metal ion; and a method for manufacturing a radiolabeled compound.

公开(公告)号：US20210060186A1

公开(公告)日：2021-03-04

申请号：US16958427

申请日：2018-12-20

Applicant: Nihon Medi-Physics Co., Ltd. ,  National Hospital Organization

Inventor： Akihiro IZAWA ,  Yuki OKUMURA ,  Yurie FUKUI ,  Hiroaki ICHIKAWA ,  Yoshifumi MAYA ,  Miho IKENAGA ,  Hiroyuki OKUDAIRA ,  Yoshihiro DOI ,  Mitsuhide NARUSE

IPC: A61K51/04 ,  C07B59/00 ,  C07D401/14

Abstract: Provided are a compound represented by the following formula (1): wherein X1 represents a hydrogen atom or a halogen atom, X2 represents a fluorine atom or a nitrile group, and X3 represents a radioactive halogen atom, or a salt thereof, and a medicament including the same.